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Abstract 
 
 
Novel Therapeutic Intervention for Myocardial infarction in large animal Model 
 
 
Maria Mercedes 
 
John Gearhart, PhD 
 
Heart failure (HF) represents an enormous clinical problem that imposes a 
significant burden both to society and survivors. During a myocardial infarction, 
cardiomyocytes are damaged due to a lack of oxygen to the left ventricle and as a result 
these cells die. The dead cells are then replaced by fibrotic scar tissue that inhibits the heart 
from properly pumping blood to the rest of the heart. The current treatments of HF do not 
reverse the damage that the left ventricle experiences and as a result many people 
experience recurrent heart failure and sometime cardiac arrest. The field of cellular 
reprogramming investigates the process of direct reprogramming of endogenous cardiac 
fibroblasts to cardiomyocytes as a novel approach to help the heart to pump blood properly 
after a myocardial infarction.  In this project, we used a biodegradable hyaluronic acid 
(HA) hydrogel to encapsulate Adeno-associated virus (AAV) 9 engineered to deliver the 
reporter gene green fluorescent protein (GFP) or five transcription factors (G: Gata4, M: 
Mef2c, T:  Tbx5, M: Mesp1and M: Myocardin) in pigs’ heart post-myocardial. Our method 
represents a unique approach to transfect cardiomyocyte cells in vivo post-myocardial 
infarct in pig. This study also demonstrates a cardiac functional improvement with the 
injection of hydrogel gel, AAV9, and selected transcription factors in the compromised 
area of the left ventricle. This novel method reduced the scar tissue in the compromised 
area of the heart compared to control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
		
	
	
	
	
	
	
2 
 
1. BACKGROUND 
 
Heart failure (HF), according to the Center for Disease Control and Prevention 
(CDC) and the American Heart Association (AHA), imposes a great financial burden to 
the United States health care systems (Benjamin et al., 2017). The AHA predicts that by 
2030, every U.S. taxpayer will pay more in taxes to care for HF; this means that every U.S. 
citizen will pay more in the cost of treating HF. The lifetime cost of HF care is very high 
primarily due to hospitalization. Currently, more Medicare dollars are expended on 
treatment of HF than on any other disease. Since HF is primarily a disease of the elderly, 
its prevalence will increase as the population ages, as shown on Fig. 1 (Heidenreich et al., 
2013). Along with the financial burden, this ailment decreases the quality of life of the 
survivors. These patients experience various emotional and physical impairment like 
fatigue, depression, chest pain, and sleeping difficulties and, as a result, mortality increases 
in this population as well (Dunlay et al., 2011).  
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Figure 1. Image adapted from Heidenreich et al., 2013. This graph shows the increase in 
direct and indirect costs attributable to HF from 2012 to 2030. 
 
HF is primarily caused by coronary artery disease (CAD), myocardial infarction 
(MI), and cardiomyopathy; these three myocardial dysfunctions result in the death of cells 
that compose the cardiac muscle (i.e. myocardial cell death). Since the adult mammalian 
heart does not regenerate, it cannot repopulate lost cardiomyocytes after HF (Li & Izpisua 
Belmonte, 2016). The left ventricle (LV) is the chamber most affected in HF and within it 
approximately 2 to 4 billion cardiomyocytes that are damaged and replaced by fibrotic scar 
tissue after a myocardial infarction (Laflamme & Murry, 2011). This maladaptive 
restorative process causes the infarcted area to electrically uncouple from the rest of the 
myocardium, and the loss of contractile function leads to recurrent heart failure (Li & 
Izpisua Belmonte, 2016). Current treatments for this illness are pharmacologic 
		
	
	
	
	
	
	
4 
intervention, changes in lifestyle, transplantation (which is very limited), cardiac device 
therapy, and palliative care (Lemond & Allen, 2011). The caveat with all of the above 
interventions is that they do not fully restore heart function. Thus, it is imperative to 
develop a new therapeutic treatment for cardiac repair.  
In order to tackle this public health problem, scientists have been developing 
different approaches to better treat MI, as shown in Figure 2 (Li & Izpisua Belmonte, 2016). 
One of these approaches is based upon the well accepted Nobel Prize winning experiments 
(i.e., induced pluripotent stem cells (iPSCs) which holds great promise but has concerning 
caveats. iPSCs are generated by forcing the expression of exogenous genes in somatic cells 
(i.e. Yamanaka factors) (Takahashi & Yamanaka, 2006). These induced cells can give rise 
to all the cells of the body, but there is a possibility that these cells may form tumors. 
Important to our study, iPSCs have been differentiated into cardiomyocytes and then 
transplanted into an ischemic heart. iPSC-derived cardiomyocytes are used to treat MI in 
mice (Rojas et al., 2017). Another challenge that these approaches face is that the induced 
cells may not electrically couple and synchronize with the host myocardium. Furthermore, 
after a decade of research with iPSCs, the mechanism of how the Yamanaka factor induces 
iPSCs is still unknown (Scudellari, 2016).  
Other therapeutic approaches include the use of fetal and adult stem cells to give 
rise to cardiomyocytes (Boyle, Schulman, Hare, & Oettgen, 2006). These alternatives have 
not been proven successful because the induced cardiomyocytes are fully differentiated 
into mature cardiomyocytes. For instance, in a stem cell experiment on non-human primate 
hearts, (Chong et al., 2014) demonstrated that the arrhythmic complications occur 
		
	
	
	
	
	
	
5 
human embryonic-stem-cell-derived cardiomyoctyes were used to treat MI. However, the 
group believe that arrhythmias could be managed by continuous surveillance and proper 
care of the animals (Murry, Chong, & Laflamme, 2014). Despite the potential of these cells 
to address HF, stem cells can also develop into teratomas. Hence, further study is important 
to develop novel therapeutic modalities to treat and perhaps cure cardiac failure. 
Another approach investigated in the field of reprogramming is direct lineage 
conversion, to change a terminally differentiated cell into another, in vivo (Fig. 2). This 
methodology relies upon the injection of transcription factors known to be involved in 
cardiomyocytes development and function directly into the compromised area of the heart 
post-MI. The target cells are cardiac fibroblasts, since these cells are abundant in the heart 
and have been successfully reprogrammed by many groups in the field.  A limitation of 
this approach is that the virus used to transfect cardiomyocytes diffuses in the heart tissue. 
As a result, the transfected cells are not found in the site of injection. Finding the transfected 
cells far away from the compromised area is a problem because the induced cells are 
required in the compromised area of the heart.  
In summary, HF is a chronic illness that imposes a burden both to society and 
patients. The costs of HF treatment to society are substantial. For patients, the burden is 
also significant because many of them experience physical limitations and psychological 
effects such as anxiety and depression. In order to address this illness, better approaches 
need to be developed to treat this ailment.   
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Figure 2. Image adapted from Li et al., 2016. Studies of different therapeutic approaches 
attempting to replace loss cardiomyocytes after myocardial infarction.  
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THESIS OBJECTIVE 
 Our laboratory wanted to know whether the AAV9 virus was an effective means of 
supplying the transcription factors to heart tissue for lineage conversion of fibroblasts to 
myocardial cells. Preliminary work from our laboratory demonstrated that injecting 
Adeno-associated virus (AAV) 9 engineered to deliver the reporter gene GFP in pig heart 
post-myocardial infarction was successful but diffuses in the compromised left ventricle. 
After serially sectioning the heart tissue where the virus was injected, the transfected cells 
were detected by immunohistochemistry far away from the point of injection. Since 
biodegradable hyaluronic acid (HA) hydrogel are known to be great delivery vehicles, we 
decided to use HA to encapsulate the virus to transfect cardiomyocytes at the site of 
injection. Hence, the objective of this thesis work was to determine if hydrogel maintain 
AVV9 virus at the point of injection and restrict diffusion of the virus and improve 
transfected cardiomyocytes post-MI in pigs. 
 
Specific Aim 1: To determine the ability of hydrogel to restrict AVV9-transfected 
cardiomyocytes diffusion from the injection site in the heart post-myocardial infarction 
in pigs. Transfected cells are to be identified by immunohistochemistry.  
 
Specific Aim 2: To determine if cardiac function of pig hearts is improved with the post-
MI injection of hydrogel-encapsulated virus carrying well-established myocardial 
transcription factors.  The cardiac functional improvement is to be assessed by MRI. 
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LITERATURE REVIEW 
In pursuit of developing a more robust treatment for myocardial infarction (MI), 
the field of regenerative medicine seeks to replace or repair the heart after HF by direct 
reprogramming of cardiac fibroblast into functional myocardial cells. Cardiac fibroblasts 
are the most abundant cells that support the heart, and hence, a great source of initial cells 
for in vivo direct reprogramming. Ieda et al. in 2010 were the first to report induced 
cardiomyocytes (iCMs) from neonatal, adult cardiac fibroblasts, & mouse tail-tip dermal 
fibroblasts by the force expression of ectopic cardiac transcription factors, such as Gata4 
(G), Mef2C (M), and Tbx5 (T) (a.k.a GMT) (Ieda et al., 2010). After this group, other 
scientists including John Gearhart’s laboratory, have improved this technique by using 
different combinations of transcription factors, microRNAs, small molecules, and using 
human cardiac fibroblasts as the initial cell source (Inagawa et al., 2012; Jayawardena et 
al., 2012; Nam et al., 2013; Qian et al., 2012; Song et al., 2012). For example, Ifkovits et 
al., demonstrated that the addition of small molecules (i.e. TGFβ inhibitor) along with 
ectopic expression of Hand2, Gata4, NKX2.5, and Tbx5 (HNGMT) was sufficient to 
induce direct reprogramming of both mouse embryonic and adult fibroblasts into mature 
cardiomyocyte cells (Ifkovits, Addis, Epstein, & Gearhart, 2014). This work was validated 
by staining for cardiac-specific markers like α-actinin, α-myosin heavy chain, myosin light 
chain 2, and myosin light chain 7 and by the expression of endogenous cardiac markers. 
Ifkovits et al. work was recently validated by an independent group in vitro and in vivo 
(Mohamed et al., 2017). These induced cardiomyocytes had strong synchronized beating 
and a similar gene expression pattern to endogenous cardiomyocyte cells. Yet whether this 
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reprogramming could occur in large mammals, and be transitioned into the clinic, remains 
unclear  
Significant understanding of the basic biology of heart development has come from 
small animal models such as mice (Xin, Olson, & Bassel-Duby, 2013). This work is 
valuable because this is how the field of reprogramming knows which genes are critical in 
the formation and proper function of the heart. One serious limitation of this work is that 
the human and mouse heart differ in heart rate, size, and oxygen consumption. As a result, 
it is challenging to use mice as animal model to generate therapeutic treatment for MI. 
Thus, a large animal model that shares physiological and pathological similarity to the 
human heart is more applicable than mice (Dixon & Spinale, 2009). The ideal large animal 
model that is clinically relevant is the pig because it’s heart resembles the human heart 
more closely in size, function, and anatomy. Hence, we are trying to see if technologies 
developed in mice can be translated into the human clinic using a porcine model  
Preliminary work from our laboratory demonstrated that in vitro reprogramming of 
adult cardiac fibroblast into cardiomyocytes is possible, as shown in Figure 3. This figure 
show the used of different transcription factor to reprogram cardiac fibroblast from pig into 
induced cardiomyocytes. When similar work was performed in vivo the transfected cells 
were low in number and not found where the virus was injected. Despite the low efficiency 
of cell expression GFP and diffusion of the virus, this work revealed that adeno-associated 
virus serotype 9 (AAV9) was effective in forcing the expression of green fluorescent 
protein (GFP) in cardiomyocytes and fibroblasts (data not shown). Furthermore, this virus 
has been demonstrated to have the capacity to infect cardiomyocytes as demonstrated by 
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Inagawa K et al., 2012; thus, this virus was selected for the in vivo experiment.  In order to 
improve our method of direct reprogramming in vivo, we decided to use hydrogel as a 
delivery system to improve the efficiency of gene delivery and retention at the infarct zone, 
which is the compromised area, and border zone, which is the histologically normal part of 
the heart.  
 
Figure 3. Adapted from unpublished data (Ifkovits 2014). Representative immunostaining 
of porcine iCMs at Day 14 in vitro. A) At day 14, staining of cTnT and Myh11 of a control 
sample of zero factor. B) Staining of cTnT of an experimental sample with the combination 
of HGMT + Myocd, C) addition of Mesp1, D) addition of NKX2.5, E) addition of KLf4, 
finally F) the combination of GMTMM. These result show early sarcomeric structures with 
the combination of different factors.  
 
Hydrogels, both natural and synthetic, have been effectively explored as a delivery 
system of cells and protein in vivo and in vitro to enhance cardiac metabolic functions post-
MI in mice and in pigs (Hasan et al., 2015) (Atluri et al., 2014; Gaffey et al., 2015). This 
delivery system has been also used for cartilage repair in a Mini-Pig model (Fisher et al., 
2016). Hydrogels are an ideal candidate for many biomedical applications because they are 
biodegradable and form injectable three-dimensional polymeric networks that retain their 
integrity and property after self-assembly (Rodell et al., 2015). Since it has been established 
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in the field of bioengineering that hydrogels are an ideal candidate for delivery of protein, 
small molecules, and cells, we experimented in delivering AAV9-GFP and AAV9-
Transcription Factors to pig hearts post-MI using hydrogels.  
 
3. MATERIALS AND METHODS 
3.1. Ethics Statement 
All the experiments concerning animals were conducted under a protocol approved by the 
University of Pennsylvania Institutional Animal Care and Use Committee. 
3.1.2 Adeno-Associated Viral Vector 9 Construction. 
Adeno-associated viral vector (AAV-9)-Cytomegalovirus (CMV)-Green Fluorescent 
Protein (GFP), red fluorescent protein mCherry, Myocyte Enhancer Factor 2C (MEF2C), 
T-Box Protein 5 (TBX5), Mesoderm Posterior BHLH Transcription Factor 1 (MESP1), 
and Myocardin (MYOCD).  
3.1.3 Hydrogel Synthesis and Preparation 
Cyclodextrin-modified HA (CD-HA), ~28% of repeat units modified, synthesis described 
elsewhere with reagents available from Sigma (St. Louis, MO) (Gaffey et al., 2015). 
3.1. 4 Experimental Design 
As shown in Fig. 5, the animals had an MRI at day 0 to assess their cardiac functional 
output and after this the infarct was induced, as explained later in the method section. Three 
days post-MI, all eleven animals underwent surgery for the injections. The infarct was first 
identified and then thin MRI compatible platinum wire was used to mark the ischemic area. 
Each injection was administered with an insulin syringe containing 200 µl of appropriate 
solution. Each animal received nine injections in the infarct and one on each side of the 
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compromised area. The injections were marked with platinum wire sutured on the 
epicardium (as shown in Fig. 5C).  
 
Figure 4. Timeline, procedure of infarction, and injections of Mep69. (A) Timeline of the 
experiment. (B) Generation of a posterolateral infarct comprising of 20% of the left 
ventricle by permanently ligating obtuse marginal arteries. (C) At day 3, the animal 
received eleven injections, shown with a blue arrow, labeled with compatible MRI 
platinum metal.  
 
3.1.3 Porcine Infarct Model 
Eleven male Yorkshire swine weighing 36-47 kg were used in this study. There were two 
groups: n=5 hydrogel/AAV9-TFs (experimental), n=6 saline (control). All the animals in 
this study had an MI. The animals were first anesthetized and sedated then, the LV free 
wall was exposed through a left thoracotomy. The animals were then sedated with 
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intramuscular ketamine injections (25-30 mg/kg), intubated, and mechanically ventilated. 
General anesthesia was maintained on mixed isoflurane (1.5-3.0%) and oxygen, which was 
delivered by volume-controlled ventilation (tidal volume 10-15 mg/kg) (Rodell et al., 
2016). A posterolateral infarction was induced by the ligation of the left circumflex artery 
(LCX) and some obtuse marginal (OM) branches. Specific arteries were not targeted 
because pigs have some variations in their artery branches. Thus, to produce a reproducible 
infarct in all the animals, the OM branches of the posterolateral area in the LV were ligated. 
This area of the posterolateral LV is defined as the area between the middle coronary vein 
and posterior coronary vein, as shown in Fig 5 and Table 1 shows the variation of ligated 
arteries that supplied blood to the LV of the animals and in all cases, this pattern of coronary 
ligations produced an infarct comprising of approximately 20% of the left ventricle. For 
the first trial of this project, animal number 69 had an infarct produced as explained below. 
On day 0, three obtuse marginal (OM) branches (i.e., OM1 – OM3) were ligated producing 
a posterolateral infarct comprising of 20% of the left ventricle. Three days post-infarct, 
100µl (total volume) of AAV9-GFP (AAV9. CMV. bi-nls. AsGFP. hGH. WPRE 
[6.08x1013 GC/ml]) and HA-hydrogel were delivered to nine sites via an insulin syringe. 
These injections were in the infarcted region and one to each side of the border zone of the 
compromised area of the left ventricle. 
3.1.4 MRI and Analysis 
Image acquisition was performed at 3T (Tim Magnetom Trio Scanner; Siemens, Inc.). For 
longitudinal analysis of myocardial geometry and function in vivo, imagining was 
performed at baseline (immediately before infarct) as well as at 2 and 4 weeks post infarct. 
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Anesthesia was maintained throughout the procedure, and cardiac gating was performed 
by placement of a pressure catheter (Millar Instruments, Inc.) in the LV. Myocardial 
geometry was assessed from 2-dimensional CINE images, with additional late gadolinium 
enhancement imaging to confirm the infarct location (Rodell et al., 2016).  
3.1.5 Histological Analysis of Pig Hearts 4 Weeks Post-MI 
Four weeks post-MI, the animal underwent the final Magnetic resonance imaging (MRI), 
and the hearts were harvested for histological examination. The hearts were cut into seven 
slices; three infarcts regions, two borders, and two remotes, as shown in Fig. 6B. The 
injection sites were cut into approximately 4 cm blocks, rinsed with 1X Phosphate-buffer 
saline, (PBS) pH 7.4 (ThermoFisher Scientific, USA) and fixed in 4% paraformaldehyde 
at 4°C for 72 hours (Sigma-Aldrich, Germany). After fixation, the tissues were serially 
dehydrated in an ethanol series (75%, 95 %, and 100% of ethanol) for 48hr (ThermoFisher 
Scientific, USA). Finally, the blocks were cut down the middle to expose the myocardium 
wall and embedded in paraffin for serial sectioning (5-10 µm).  To assess the infarcts, the 
tissues were stained with Hematoxylin and Eosin and Masson’s Trichrome by the 
Cardiovascular Research Center (Histology and Gene Expression Core) at the University 
of Pennsylvania.  
3.1.6 Immunohistochemistry Staining for Pig’s Heart 
 
Sectioned tissues were deparaffinized and rehydrated: xylene two times for 5 minutes 
(min), 50% xylene/ethanol for 5 more min, followed by 3 min incubations each in 100%, 
95%, 75%, and 50% ethanol, and finally 3 min in tap water. Antigen retrieval was 
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performed with citrate buffer (97°C for 20 minutes followed by cooling to room 
temperature for 20 minutes) and rinsed with 0.1% PBS-Triton (PBST).  
Slides were incubated with blocking buffer (e.g. 10% goat serum in 1% Bovine serum 
albumin (BSA)) for 1 hour at room temperature and the tissue was then incubated with the 
appropriate antibody mixture overnight at 4°C. The slides were rinsed for PBST 3 times 
for 10 min at room temperature followed by incubation with the appropriate secondary 
antibody for 1 hour at room temperature. The tissues were again rinsed with PBST 3 times 
for 10 min at room temperature. Then, incubated with 70% of ethanol for 5 min. The pig 
heart has a great amount of autofluorescence and therefore the tissues are incubated for 15 
min at room temperature with an Autofluorescence Eliminator reagent (Millipore, USA). 
This reagent stains the tissues blue -  and in order to remove this color and any Sudan black 
precipitate - the sample is rinsed multiple times with 70% of ethanol followed by a final 
wash with 1x PBS for 10 min and mounted with ProLong Gold antifade plus DAPI 
(ThermoFisher Scientific, USA).  To examine the expression of the reporters (mCherry or 
GPF) or the V5-tagged transcription factors, the tissues were with stained with antibody 
against mCherry, GPF, or V5.  
3.1.7 Image acquisition 
Microscopic images were taken under fluorescence microscopy at 10X, 20X, and 40X 
magnification and assessed with Fiji (ImageJ) (Schindelin et al., 2012). 
3.1.8 Statistical Analysis 
GraphPad Prism 7 was used to compared the groups. Randomization was not applied.  
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Results 
 
In the first part of this study, one pig (Mep69) was used to test the ability of 
hydrogel to improve transfection of cardiomyocytes with AAV9 expressing GFP (Fig. 5).  
  
          
Figure. 5. A diagram of the Hydrogel, AAV-9.CMV.eGFP plasmid, the mixture of the 
virus and plasmid for injections used in the experiment. (A) Schematic of dynamic cross-
link formation utilizing guess-host chemistry. (B) AAV-9.CMV.eGFP plasmid used in this 
experiment. (C) The mixture of the plasmid/AVV9 and hydrogel. (D) The mixture of virus 
and hydrogel was then used to inject the animal.  
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This animal had an induced infarct at day 0 and three days post-MI, eleven injections of 
AAV9-GFP encapsulated in hydrogel were given to the animal (Fig. 4). At day 18 post-
MI, the animal was sacrificed and heart tissue collected for examination (Fig 6).  
 
Figure 6. At day 18, the animal was sacrificed and the tissue was collected for analysis. 
(A) The heart was removed from the animal and evaluated to identify the infarct. (B) The 
infarcted and border zones were cut into slices. (C) The thickness of the remote, infarct, 
and border zone were measured. 
 
Both the compromised and border zones (that is healthy surrounding tissue) were collected 
for immunohistochemistry and established markers of cardiomyocyte identity like cardiac 
Troponin were used to stain the tissues. The GFP-adenovirus transduced cells (GFP+) were 
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found within most of these two zones along with overlapping expression of GFP and 
cardiac Troponin T (cTnT or TnnT2), a cardiomyocyte marker (Figure 7).  
 
Figure 7. Immunofluorescence imaging of GFP+ cells, 18-days post-MI. Sections were 
mounted with DAPI (blue) and stained for GFP (green) and cTnT (red). Representative 
images of injection sites of the infarct and border zone. These are representative images of 
GFP+ cells at sites A, B, C and D of the infarct zone. Scale bar of 20µm. This figure 
demonstrates the expression of GFP in cardiomyocytes cells in the infarct and border zone. 
 
GFP+ cells were immunopositive for cardiomyocytes and for vimentin (a fibroblast 
marker), and b-actin cells. However, there were no cells immunopositive for CD34 (a 
hematopoietic and endothelial marker), as shown in figure 8. 
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Figure 8. Co-staining of different markers to identify which cells expressed GFP. (A) 
Staining of vimentin (red), a fibroblast marker, (B) cTnT (red) stains for cardiomyocytes, 
(C) b-Actin (red) a smooth muscle cells marker, and (D) CD34 (red) an endothelial marker. 
Scale bar of 20µm. This image shows the expression of GFP mostly in cardiomyocytes and 
fibroblasts. 
 
 Hydrogel residue was not detected in the tissue used for analysis, which is consistent with 
a previous report of in vivo degradation (Dorsey et al, 2015).  
This result stood in stark contrast to our earlier studies where few cells were found 
to be transduced when the GFP adenoviruses were used.  In the pig Mep69, we could easily 
count the number of GFP-transduced cells within the hydrogel co-injected sites; but in our 
earlier studies there were very low number of positive cells. With the hydrogel, it was 
easier to find the location of the injection tract in the tissue making it easier to identify the 
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locations of the GFP+ cells in both the compromised area and the histologically normal 
areas. Our data strongly suggests that this injectable system increases virus retention during 
and after injections, with many GFP positive cells, demonstrating the efficiency of 
hydrogel as a potential therapeutic delivery system to treat HF.  
Since the first experiment was very encouraging, we decided to continue with this 
experiment but with more animals to perform in vivo reprogramming. In order to test in 
vivo reprogramming in pigs, the combination of the following transcription factors (TFs) 
were used: Gata4, Mef2c, Tbx5, Mesp1, and Myocardin (GMTMM). This mixture of TFs 
was used to reprogram both mouse and human fibroblast cells into cardiomyocytes in vitro 
(Wada et al., 2013) and was validated by our laboratory.  
In the second part of this project, we kept the animals alive for one more week and 
MRI analysis was performed before the infarct was induced, at two weeks post-MI, and at 
four weeks post-MI, just before the heart was harvested (Diagram 1). This time, there were 
two groups: n=5 hydrogel/AAV9-TFs (experimental), n=6 saline (control) (Table 1).  
 
Diagram 1. Timeline of the second part of the experiment.  
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Table 1. Detailed records of how the infarct was induced, weight of animals, infarct sites, 
number of injections, and size of the compromise tissues. Abbreviations: G (hydrogel), V 
(AAV9), and TF (transcription factors), OM (obtuse marginal) and PD (posterior 
descending) 
 
The number of injections, tissue collection, and analysis were the same as previously 
described for Mep69 (Fig. 5B & 5C and Fig. 6). Immunohistochemistry was also 
performed to detect the V5-tag expressed on each of the transcription factors in the same 
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manner as for Mep69. Cells immunopositive for V5 was strong, as shown in Fig. 9. 
 
Figure 9. Representative images of immunohistochemistry of heart tissues in both 
experimental and control groups, 4 weeks post-MI. Sections were mounted with DAPI 
(blue) and stained for V5 (red) and TnnT2 (green). (A) and (B) are co-staining of TnnT2/V5 
in the infarct zone. The white arrows on (A) points at V5+ cells in cardiomyocytes. Scale 
bar of 20µm. This image shows the expression of V5 in cardiomyocytes. 
 
Moreover, in order to detect the formation of scar tissue or fibrosis, Masson’s Trichrome 
staining (Fig. 10) was performed in both groups (i.e. experimental and control). 
According to this staining, there is cardiomyocytes in the infarct zone of the experimental 
animals.  
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Figure 10. Representative images of trichrome staining. Trichrome staining of the infarct 
zone of experimental (A) and (B) group 4-weeks post-MI. Scale bar of 20µm. 
 
 The final analysis, clinically relevant to MI, was the assessment of cardiac 
function. A healthy human heart is one that has the ability to hold approximately 120ml of 
blood in the left ventricle before contraction; a process known as left ventricle end-diastolic 
volume (EDV). After the heart contracts, 50ml of blood is left in the ventricle; this ejection 
of blood into the aorta is called left ventricle end-systolic volume (ESV) and the measured 
difference of EDV-ESV is the ejection fraction (EF). After an MI, the heart forms scar 
tissues that reduces ventricular contractility, thereby affecting EDV, ESV, and EF.  
Before the animals had the infarct, their left ventricle was functioning normally 
(Fig. 11, Baseline). However, after the infarct was induced, cardiac function was evaluated 
at two weeks and four weeks post-infarct, control (saline treated) animals had difficulty 
contracting their left ventricle (Fig. 11). In contrast, the experimental group appeared to 
have a small recovery of left ventriclular contractivity as ejection fraction increased by 4-
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weeks post-MI.  This result indicates that the use of these transcription factors, along with 
hydrogen, enable the left ventricle to regain contractility.  
 
Figure 11. Magnetic resonance imaging (MRI) assessment of cardiac function. MRI 
measurements of left ventricular end-diastolic volume (EDV) (A), left ventricular end-
systolic volume (ESV)(B), and ejection fraction (EF)(C). This figure demonstrates a 
functional cardiac volume improvement in the experimental animal compared to the 
control. P-values: EDV two weeks p <0.0001 ****, EDV four weeks P value 0.0007 ***, 
ESV two weeks p value 0.0009***, ESV 4 Weeks: P value 0.0001 ***, and EF 4 Weeks: 
P value <0.0001 ****. 
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Discussion 
The field of cellular reprogramming, particularly the conversion of fibroblast cells 
into cardiomyocytes to treat MI, has come a long way (Doppler, Deutsch, Lange, & Krane, 
2015).  For example, it has taken the field almost a decade to determine which transcription 
factors, microRNAs and small molecules are necessary to generate induced 
cardiomyocytes, though the efficiency of induction remains very low, both in vivo and in 
vitro. This is a problem because an infarcted heart will likely require a large number of 
mature contractible cells to regain normal function. In order to address this issue, many 
laboratories have repeated published work of reprogramming to increase the efficiency of 
induced cardiomyocytes, but the results are unfortunately not reproducible. According to 
Doppler et al., 2015, one way to move the field forward, would be to conduct more studies 
to understand the epigenetics of this technology and improve viral delivery (as shown in 
figure 12).  
Our goal is to reprogram cardiac fibroblasts into cardioyocytes because fibroblasts 
are the most abundant cells in the heart and are the cells recruited during healing process 
into the ischemic area of the heart to form scar tissue (Doppler et al., 2015; Prabhu & 
Frangogiannis, 2016). To our knowledge, this is the first study to attempt in vivo 
reprogramming in a large animal model, such as a pig, with the combination of GMTMM, 
post-MI. This study is also the first in furthering the field of reprogramming to develop a 
treatment for the pathological condition created by MI. Our results show that the 
biodegradable hyaluronic acid hydrogel is effective in delivering AAV9 at the point of 
injection (figure 9), and that the delivered combination of transcription factors improved 
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cardiac function in the experimental group compared with the control animals (figure 11). 
Although, we lack the data that could explain the mechanism that is driving this outcome, 
future experiments could test if the combination of these factors rescue compromised 
cardiac cells or differentiate endogenous fibroblasts into new cardiomyocytes of the left 
ventricle post-MI. The following discusses some experimental modifications for 
investigating the mechanisms. 
First, the CMV promoter driving the TFs in the virus is not specific to fibroblast 
cells but drives TF expression in many other cell types (Fig. 8). However, this promoter 
proved successful in vitro in inducing the expression of GFP in pig cardiac fibroblast cells 
in contrast to a specific promoter for fibroblast cells, for example Vimentin (data not 
shown). The second limitation of this study is that all the factors are upstream of the same 
protein tag. This epitope tagged protein is called V5 and it enables the detections of the 
factors by immunochemical methods providing an indirect visualization of where the TFs 
are being expressed and translated. The caveat of tagging all the factors with the same tag, 
V5, is that factors cannot be distinguished from each other. (Fig 9). In the future, this can 
be fix by using different protein tags like mCherry and GFP. 
Finally, these pigs are not transgenic and thus it is difficult to trace endogenous 
fibroblast cells that become novel cardiomyocytes with the forced expression of GMTMM 
post-MI, like in mice. Earlier reprogramming studies in vivo have been performed in 
transgenic mice harboring cardiac fibroblast-specific markers such as vimentin, Fibroblast-
specific protein-1 or periostin, allowing one to genetically track the fate of endogenous 
cardiac fibroblasts in vivo and investigate if reprogramming is actually occurring in the 
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targeted cells. This type of study also reveals the lineage of the cells that were converted 
into cardiomyocytes. The creation of transgenic pigs is not impossible or unheard of in 
biomedical research (Aigner et al., 2010), but a challenge of using transgenic pigs is that 
the process is costly and time consuming.  
  
 
Figure 12. Image adapted from (Doppler et al., 2015). Before direct reprogramming is 
done in humans, the efficiency of induced cardiomyocytes needs to be increased. Further 
studies are necessary to understand the mechanism of this technology as this is a safety 
concern.   
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Conclusions 
In summary, heart failure is an important health care issue because of its morbidity, 
cost of care, and mortality. Heart failure, which is one of the leading causes of death in the 
United States (Benjamin et al., 2017), is a consequence of Myocardial infarction (MI) also 
known as a heart attack due to the loss of blood flow and oxygen delivery to the cardiac 
tissue. If the MI is survived, the death of the hypoxic cardiac tissue results in a 
dysfunctional scar tissue that renders the individual more susceptible to further heart 
failure, hence, a treatment for this post-MI, pathological state is imperative. The current 
treatments of MI do not reverse the damage that the heart suffers from a heart attack and 
are incapable of making the heart generate new cardiomyocytes to replace the scar tissues 
that form after an MI. Reversing and redirecting the fate of mature cardiac fibroblasts into 
induced cardiomyocytes in vivo after an MI is an intriguing therapeutic modality. These 
cells have been extensively explored as an initial cell source for reprogramming into 
different kinds of cells.  
In this study, we investigated the ability of a hyaluronic acid (HA) hydrogel to 
efficiently deliver a viral vector of transcription factors to post-MI pig hearts with the aim 
of increasing the number of functional cardiomyocytes in the damaged area of cardiac 
tissue. Our results suggest, a hydrogel was capable of delivering and retaining the viral 
vector at the sites of interest. This was shown by the staining of GFP+ cells and V5+ cells 
in the infarction. Moreover, our result also shows that using the combination of 
transcription factors Gata4, Mef2c, Tbx5, Mesp1, and Myocardin (GMTMM) carried in 
the hydrogel-embedded Adeno-Associated Virus (AVV9) leads to a modest recovery of 
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left ventrical ejection fraction as assessed by functional MRI imaging of the pig hearts.  
Our work is a proof-of-concept in the treatment of MI-damaged cardiac tissue.   
In summary, these findings illustrate the value of using a combination of hydrogel 
and AVV9 for delivery of in vivo transcription factors as potential therapeutic treatment 
after MI. Intramyocardial injections of hydrogel and AVV9-TFs-V5 help reduce scar size 
of the MI, leading to an improvement in diastolic and systolic function. These findings 
have important clinical implications for future investigations of gene therapy for heart 
disease.  
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Appendix A: List of Software used 
 
Fiji (ImageJ) 
 
GraphPad Prism 7 
 
 
 
 
Appendix B: List of statistical test 
t-test 
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